KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EBITDA (2016 - 2025)

Historic EBITDA for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $491.7 million.

  • Resmed's EBITDA rose 1783.54% to $491.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 1657.64%. This contributed to the annual value of $1.8 billion for FY2025, which is 2756.76% up from last year.
  • Latest data reveals that Resmed reported EBITDA of $491.7 million as of Q4 2025, which was up 1783.54% from $446.5 million recorded in Q3 2025.
  • Resmed's 5-year EBITDA high stood at $491.7 million for Q4 2025, and its period low was $223.4 million during Q1 2021.
  • For the 5-year period, Resmed's EBITDA averaged around $327.0 million, with its median value being $284.6 million (2022).
  • As far as peak fluctuations go, Resmed's EBITDA plummeted by 182.02% in 2023, and later soared by 5167.29% in 2024.
  • Quarter analysis of 5 years shows Resmed's EBITDA stood at $248.7 million in 2021, then grew by 12.66% to $280.2 million in 2022, then dropped by 1.82% to $275.1 million in 2023, then soared by 51.67% to $417.2 million in 2024, then grew by 17.84% to $491.7 million in 2025.
  • Its last three reported values are $491.7 million in Q4 2025, $446.5 million for Q3 2025, and $454.5 million during Q2 2025.